ZT

Zoetis Inc

ZTS
Accountable AI Logo

Zoetis Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-08

Snapshot

  • Operating margin 37.6% TTM vs industry median ~0% - dominant pricing power in animal health niche with minimal competition[Operating Margin TTM]
  • ROE 49.9% TTM with ROIC 21.5% - exceptional capital efficiency despite 1.35x debt/equity leverage[ROE TTM]
  • FCF 2.2B TTM (24% of revenue) funds 394M buybacks + 222M dividends while maintaining 2.1B cash buffer[Free Cash Flow TTM]

Watch Triggers

  • Operating Margin TTM: Falls below 32%Signals pricing power erosion or generic competition - thesis invalidating
  • Free Cash Flow TTM: Drops below 1.8BWould force choice between buybacks and debt service at current leverage
  • Goodwill: Impairment charge announced2.8B goodwill (51% of equity) - any write-down materially impacts book value

Bull Case

Near-monopoly economics: 71.7% gross margin, 37.6% operating margin, 21.5% ROIC - structural moat in fragmented animal pharma market with high switching costs

Gross Margin TTMOperating Margin TTMROIC TTM

Cash machine: 2.2B FCF TTM with capex only 7.2% of revenue enables aggressive capital return (616M TTM) without impairing growth

Free Cash Flow TTMCapital Expenditure TTM

Bear Case

Premium valuation: P/E 19.4x near industry median 20.2x but P/B 32.9x reflects intangibles risk - goodwill 2.8B is 51% of equity

PE RatioPB RatioGoodwill

Leverage exposure: 7.3B total debt at 1.35x D/E with 216M interest expense TTM - rising rates compress 16.4x interest coverage

Total DebtDebt to EquityInterest Expense TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
65%

Leverage ZTS's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Pet humanization trend sustains premium pricing power through 2027

1-3yhigh
  • 37.6% operating margin indicates inelastic demand
  • R&D 685M TTM (7.3% of revenue) builds pipeline moat
  • Gross margin 71.7% enables continued reinvestment
Operating margin 37.6% vs industry ~0%Net margin 28.2% TTM sustainedFCF conversion 77% of net income
Valuation Context
Caveats

Public Strategies Rankings

See how Zoetis Inc ranks across different investment strategies.

Leverage ZTS's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.